Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - HC Wainwright upped their FY2024 earnings per share (EPS) estimates for Monopar Therapeutics in a note issued to investors on Monday, November 11th. HC Wainwright analyst S. Lee now expects that the company will post earnings of ($1.68) per share for the year, up from their prior forecast of ($2.06). HC Wainwright has a "Buy" rating and a $22.00 price objective on the stock. The consensus estimate for Monopar Therapeutics' current full-year earnings is ($1.84) per share. HC Wainwright also issued estimates for Monopar Therapeutics' Q4 2024 earnings at ($0.34) EPS, Q1 2025 earnings at ($0.35) EPS, Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.40) EPS and FY2025 earnings at ($1.48) EPS.
Separately, Rodman & Renshaw assumed coverage on Monopar Therapeutics in a research report on Friday, October 11th. They set a "buy" rating and a $50.00 price objective on the stock.
Check Out Our Latest Analysis on Monopar Therapeutics
Monopar Therapeutics Stock Down 5.2 %
NASDAQ MNPR traded down $1.00 on Thursday, reaching $18.23. The stock had a trading volume of 104,018 shares, compared to its average volume of 687,112. Monopar Therapeutics has a 12-month low of $1.37 and a 12-month high of $38.50. The stock has a fifty day moving average price of $8.47 and a two-hundred day moving average price of $5.10. The firm has a market capitalization of $96.25 million, a price-to-earnings ratio of -8.85 and a beta of 1.09.
Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last announced its earnings results on Friday, November 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.46) by $0.09.
Insider Activity at Monopar Therapeutics
In related news, CFO Karthik Radhakrishnan acquired 1,550 shares of the firm's stock in a transaction on Monday, October 28th. The stock was bought at an average price of $16.25 per share, for a total transaction of $25,187.50. Following the completion of the purchase, the chief financial officer now directly owns 1,550 shares of the company's stock, valued at approximately $25,187.50. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 34.90% of the stock is currently owned by corporate insiders.
About Monopar Therapeutics
(
Get Free Report)
Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
Read More
Before you consider Monopar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monopar Therapeutics wasn't on the list.
While Monopar Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
